BNP Paribas Financial Markets
DMAAR

BNP Paribas Financial Markets’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

BNP Paribas Financial Markets’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.18K Hold
119,686
– – ﹤0.01% 5271
2025
Q4 		$22.4K Buy
+119,686
New +$23.2K ﹤0.01% 4986

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

BNP Paribas Financial Markets's DMAAR Position: Q1 2026 in Review

BNP Paribas Financial Markets held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q1 2026 at 119,686 shares worth $7.18K. The position accounts for ﹤0.01% of the portfolio, ranked #5271.

BNP Paribas Financial Markets first reported a position in DMAAR in Q4 2025 and has held it in 2 quarters since. The position peaked at $22.4K in Q4 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

  • BNP Paribas Financial Markets held 119,686 shares of Drugs Made In America Acquisition Corp Rights worth $7.18K as of Q1 2026.
  • BNP Paribas Financial Markets left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q1 2026.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5271 holding.
  • BNP Paribas Financial Markets first reported a position in Drugs Made In America Acquisition Corp Rights in Q4 2025 and has held it in 2 quarters since.
  • BNP Paribas Financial Markets's Drugs Made In America Acquisition Corp Rights position peaked at $22.4K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.